Of the three Danoprevir trials you cited, only one (http://clinicaltrials.gov/ct2/show/NCT01220947 ) supports your contention that the drug might not be dead. One of the other two trials started in mid 2009 (and is costing Roche essentially nothing to continue) and the other trial has not actually started. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.